Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
Department of Urology, Affiliated Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi, Jiangsu, China.
Front Cell Infect Microbiol. 2023 Jun 28;13:1169909. doi: 10.3389/fcimb.2023.1169909. eCollection 2023.
To establish antibiotic preregimes and administration routes for studies on urinary microbiota.
Antibiotics for enteritis (Abx-enteritis) and UTIs (Abx-UTI) were administered via gavage and/or urinary catheterisation (UC) for 1 and/or 2 weeks. The effects of these Abx on the urinary microbiota of rats were examined via 16S rRNA sequencing and urine culture, including anaerobic and aerobic culture. Additionally, the safety of the Abx was examined.
Abx-enteritis/Abx-UTI (0.5 g/L and 1 g/L) administered via gavage did not alter the microbial community and bacterial diversity in the urine of rats (FDR > 0.05); however, Abx-UTI (1 g/L) administered via UC for 1 and 2 weeks altered the urinary microbial community (FDR < 0.05). Rats administered Abx-UTI (1 g/L) via UC for 1 week demonstrated a distinct urinary microbiota in culture. Abx-enteritis/Abx-UTI administered via gavage disrupted the microbial community and reduced bacterial diversity in the faeces of rats (FDR < 0.05), and Abx-UTI administered via UC for 2 weeks (FDR < 0.05) altered the fecal microbiota. Abx-UTI (1 g/L) administered via UC did not alter safety considerations. In addition, we noticed that UC did not induce infections and injuries to the bladder and kidney tissues.
Administration of Abx-UTI via UC for 1 week can be considered a pre-treatment option while investigating the urinary microbiota.
为了建立用于尿液微生物组研究的抗生素预处理方案和给药途径。
采用灌胃和/或导尿(UC)的方式,给予肠炎(Abx-enteritis)和尿路感染(Abx-UTI)抗生素 1 至 2 周。通过 16S rRNA 测序和尿液培养,包括厌氧和需氧培养,检查这些抗生素对大鼠尿液微生物组的影响。此外,还检查了抗生素的安全性。
通过灌胃给予的 Abx-enteritis/Abx-UTI(0.5 g/L 和 1 g/L)不会改变大鼠尿液中的微生物群落和细菌多样性(FDR > 0.05);然而,通过 UC 给予的 Abx-UTI(1 g/L)持续 1 至 2 周会改变尿液微生物群落(FDR < 0.05)。通过 UC 给予 Abx-UTI(1 g/L)1 周的大鼠在培养中表现出独特的尿液微生物群。通过灌胃给予的 Abx-enteritis/Abx-UTI 会破坏大鼠粪便中的微生物群落并降低细菌多样性(FDR < 0.05),而通过 UC 给予的 Abx-UTI 持续 2 周(FDR < 0.05)会改变粪便微生物群。通过 UC 给予的 Abx-UTI(1 g/L)不会改变安全性考虑因素。此外,我们注意到 UC 不会引起膀胱和肾脏组织的感染和损伤。
在研究尿液微生物组时,通过 UC 给予 Abx-UTI 持续 1 周可以被视为一种预处理方案。